These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8808461)

  • 1. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
    ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological studies in uremic and kidney transplanted patients.
    Langhoff E
    Dan Med Bull; 1989 Apr; 36(2):160-75. PubMed ID: 2651030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of uremic sera on the blastic transformation of lymphocytes of healthy subjects, stimulated with non-specific mitogens (PHA, con A, PWM).
    Klinger M; Kuczera J; Kruzel E
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):73-82. PubMed ID: 7416921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A and prednisolone: an additive inhibitory effect of cell proliferation and interleukin-2 production.
    Manfro RC; Pohanka E; Tomlanovich S; Benet LZ; Garovoy MR
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1457-9. PubMed ID: 2523586
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of the alpha 2-HS-glycoprotein on the mitogen-induced lymphoblastic transformation and IL-2 production.
    Jakab L; Jakab L; Kalabay L; Pozsonyi T; Cseh K
    Acta Physiol Hung; 1991; 77(1):25-31. PubMed ID: 1950589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of uremic serum and 3'-5' cyclic AMP on blastogenesis of normal lymphocytes.
    Modai D; Weissgarten J; Cohen N; Averbukh Z; Golik A; Peller S; Tieder M; Shaked U; Kaufman S
    Thymus; 1986; 8(5):307-11. PubMed ID: 3026066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro reactivity of lymphocytes obtained from uraemic patients maintained by heamodialysis.
    Sengar DP; Rashid A; Harris JE
    Clin Exp Immunol; 1975 Aug; 21(2):298-305. PubMed ID: 126831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance.
    Walker KB; Potter JM; House AK
    Clin Exp Immunol; 1987 Apr; 68(1):162-7. PubMed ID: 3498565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of varying dialysis regimens on lymphocyte stimulation.
    Hurst KS; Saldanha LF; Steinberg SM; Galen MA; Lowrie EG; Gagneux SA; Lazarus JM; Strom TB; Carpenter CB; Merrill JP
    Trans Am Soc Artif Intern Organs; 1975; 21():329-34. PubMed ID: 1146004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro immune functions in patients with minor, moderate, and severe kidney impairment.
    Langhoff E; Ladefoged J
    APMIS; 1988 Jul; 96(7):655-9. PubMed ID: 3261594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interleukin-2 and methylprednisolone on in vitro transformation of uremic lymphocytes.
    Langhoff E; Ladefoged J; Odum N
    Int Arch Allergy Appl Immunol; 1986; 81(1):5-11. PubMed ID: 3488966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic heparinization of uremic patients and its effects on blood lipids and on in vitro toxicity of the plasma.
    Wessel-Aas T; Christophersen B
    Clin Nephrol; 1982 Sep; 18(3):135-40. PubMed ID: 7140025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergetic effect of dialyzer membrane and lipopolysaccharide on peripheral blood mononuclear cell cytokine production in uremic patients.
    Gu Y; Ding F; Qin H; Zhao H; Lin S
    Chin Med J (Engl); 2000 Apr; 113(4):315-9. PubMed ID: 11775226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune deficiency of the uremic patient.
    Chatenoud L; Herbelin A; Beaurain G; Descamps-Latscha B
    Adv Nephrol Necker Hosp; 1990; 19():259-74. PubMed ID: 2105582
    [No Abstract]   [Full Text] [Related]  

  • 17. Fractions of middle molecular weight responsible for immunodeficiency in malnourished and burnt patients.
    Gay G; Touraine JL; Touraine F; Freyria AM; Traeger J; Navarro J
    Artif Organs; 1981; 4 Suppl():71-5. PubMed ID: 6794551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro cytotoxic properties of plasma samples from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells.
    Higuchi T; Fukuda N; Yamamoto C; Yamazaki T; Oikawa O; Ohnishi Y; Okada K; Soma M; Matsumoto K
    Ther Apher Dial; 2006 Feb; 10(1):65-71. PubMed ID: 16556139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLC-blocking factors in uremic sera.
    Fehrman I; Ringdén O; Bergström J
    Clin Nephrol; 1980 Oct; 14(4):183-9. PubMed ID: 7000408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.